Filtered By:
Condition: Cholesterol
Drug: Zivast
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1401 results found since Jan 2013.
Pravastatin for lowering lipids
CONCLUSIONS: Pravastatin lowers blood total cholesterol, LDL cholesterol and triglyceride in a dose-dependent linear fashion. This review did not provide a good estimate of the incidence of harms associated with pravastatin because of the lack of reporting of adverse effects in 48.4% of the randomized placebo-controlled trials.PMID:37721222 | DOI:10.1002/14651858.CD013673.pub2
Source: Cochrane Database of Systematic Reviews - September 18, 2023 Category: General Medicine Authors: Stephen P Adams Nima Alaeiilkhchi Sara Tasnim James M Wright Source Type: research
Variability in Plasma Lipids Between Intensive Statin Therapy and Conventional-Dose Statins Combined with Ezetimibe Therapy in Patients with Coronary Atherosclerosis Disease
In this study, we aimed to examine the variability in plasma lipids under two different lipid-lowering regimens (intensive statin therapy versus the combination of conventional-dose statins with ezetimibe). In total, we have retrospectively examined 1275 patients with CAD from January 2009 to April 2019 and divided them into two groups: intensive statin group and conventional-dose statins combined with ezetimibe group. All patients were followed up for at least 1 year. Lipid variability was verified by standard deviation (SD), coefficient of variation (CV), and variability independent of mean (VIM) triple methods. Multiple...
Source: Atherosclerosis - September 13, 2023 Category: Cardiology Authors: Jinhua Jin Liwen Shan Manjun Wang Lu Liu Tian Xu Duanbin Li Zhezhe Chen Xianglan Liu Wenbin Zhang Ya Li Source Type: research
Effects and mechanism of Kedaling tablets for atherosclerosis treatment based on network pharmacology, molecular docking and experimental study
CONCLUSIONS: KDL attenuated AS in ApoE-/- mice, which was associated with a suppression of inflammatory signalling through the TNF and TGF-β pathways.PMID:37657772 | DOI:10.1016/j.jep.2023.117108
Source: Atherosclerosis - September 1, 2023 Category: Cardiology Authors: Hongzheng Li Wenwen Yang Weiyi Cao Zikai Yu Guoyuan Zhang Linzi Long Hao Guo Hua Qu Changgeng Fu Keji Chen Source Type: research
Effect of Statins on Superoxide Dismutase Level: A Systematic Review
CONCLUSION: Our systematic review suggests that treatment with statins has a positive effect on SOD activity. However, evidence from further randomized controlled trials is required to confirm the potential antioxidant effect of statin therapy.PMID:37653630 | DOI:10.2174/0929867331666230831145809
Source: Current Medicinal Chemistry - September 1, 2023 Category: Chemistry Authors: Mahla Daliri Luis E Simental-Mend ía Tannaz Jamialahmadi Prashant Kesharwani Željko Reiner Amirhossein Sahebkar Source Type: research
Statins, allies against antibiotic resistance?
Curr Med Chem. 2023 Aug 29. doi: 10.2174/0929867331666230829141301. Online ahead of print.ABSTRACTDue to the ever-increasing rate of antibacterial resistance, the search for effective antibacterial agents has become imperative. Researchers have investigated the potential antimicrobial properties of various classes of nonantibiotic drugs. Statins are a group of antihyperlipidemic drugs with several cholesterol-independent effects, including anti-inflammatory, immune-modulating, antioxidant, and antibacterial effects. In vitro and in vivo studies have demonstrated the antibacterial properties of statins against various gram-...
Source: Current Medicinal Chemistry - August 30, 2023 Category: Chemistry Authors: Mohammad Abavisani Melika Hoseinzadeh Reza Khayami Mansoor Kodori Saman Soleimanpour Amirhossein Sahebkar Source Type: research
Atorvastatin reduces renal interstitial fibrosis caused by unilateral ureteral obstruction through inhibiting the transcriptional activity of YAP
In this study, we established a mouse model of obstructive kidney disease induced by unilateral ureteral obstruction (UUO). The UUO procedure significantly upregulated YAP and fibrosis-related gene expression in a time-dependent manner. Morphologically, the renal fibrotic lesions associated with hydronephrosis progressively worsened over time in the UUO group. Atorvastatin, which is widely used to lower blood cholesterol levels, has recently been shown to inhibit Yes1 associated protein (YAP). We treated UUO mice with atorvastatin for 3 and 10 days and observed a decrease in the expression of YAP and fibrosis-related genes...
Source: Biochemical and Biophysical Research communications - August 26, 2023 Category: Biochemistry Authors: Jun Wang Zhichao Wang Fan Xia Qiong Duan Xiaoping Peng Source Type: research
Statins and immune-mediated necrotizing myopathy: Variability in the risk
CONCLUSION: Atorvastatin presents the highest risk of IMNM. Our data suggest that the occurrence of IMNM is a class effect.PMID:37625939 | DOI:10.1016/j.therap.2023.07.005
Source: Therapie - August 25, 2023 Category: Psychiatry & Psychology Authors: Thierry Trenque Jed Hadjoudj Agathe Trenque Federica Tralongo Salom é Martin Brahim Azzouz Source Type: research
